PACTT

News

Lymphatica Medtech, une spin-off de l’EPFL et du CHUV, annonce un financement de série A à 7 chiffres

December 4, 2020

Le PACTT est heureux de partager la bonne nouvelle de clôture du second cycle d’investissement réalisé par Lymphatica Medtech avec un financement de série A à 7 chiffres ! Ce tour de financement a été dirigé par High Tech Gründerfonds (https://www.htgf.de/en/), un fonds de capital à risque allemand émérite.

Cette nouvelle étape de financement va permettre à Lymphatica Medtech d’avancer dans ses essais cliniques et d’améliorer la convivialité et la numérisation de son produit LymphoDRAIN (dispositif implantable pour le traitement du Lymphoedème chronique).

Lymphatica Medtech est une spin-off de l’EPFL et du CHUV créée en 2017 qui avait, à ses débuts, obtenu le soutien de Venture Kick et du Canton de Vaud (prêt FIT). La start-up continue aujourd’hui de travailler en collaboration avec la Professeure Lucia Mazzolai qui dirige le Département Cœur-Vaisseaux du CHUV.

Le PACTT est fier de cette nouvelle étape franchie par l’équipe de Lymphatica Medtech et lui souhaite plein succès!

Lire le communiqué de presse de Lymphatica Medtech

bench2biz : An intense workshop for aspiring entrepreneurs in science & technology

September 24, 2020

Bench2biz consortium‘s next pre-seed workshop will be held online from November 23rd to December 4th, 2020 entitling 20 hours spread over two weeks, to host idea champions from all over Switzerland.

The workshop targets very early to early high-technology entrepreneurial ideas from all fields and prepares for the entry into the existing Swiss start-up promotion ecosystem.

If you are wondering if your invention/research is marketable,
If you need to get a clear picture on how to pursue your business idea,
If you want to get guidance specifically adapted to your project,
Then, the bench2biz is the right workshop for you! You will benefit from fast-paced sessions, support from recognized industry experts and networking opportunities.

APPLY NOW!

Application: please fill in the application form.
Deadline for application: October 31st, 2020.
When: November 23 to December 4, 2020 – see detail agenda.
Where: On Zoom. High- security end-to-end encryption is ensured.

Application and participation are free of charge.
Contact & Info: info@bench2biz.ch – https://bench2biz.ch

InnoPACTT: a financial support to create your start-up

August 27, 2020
 

Autumn CALL 2020

You are a UNIL-CHUV researcher who would like to create a start-up and need a financial support to start?

Apply for a one-year InnoTREK grant of CHF 100’000.- to launch your project!

 

PACTT, the Technology Transfer Office of UNIL-CHUV, is calling for start-up projects in order to award the InnoTREK grant. As part of the InnoPACTT financial support, the InnoTREK grant is designed to accelerate innovation and UNIL-CHUV spin-off creation, and to encourage researchers with innovative ideas to jump into the entrepreneurship adventure.

Deadline for submission: September 25, 2020

For conditions, registration form and information: www.pactt.ch/innotrek/

Contact: innopactt.info@chuv.ch

021 314 39 84 / 021 314 49 58 / 021 314 82 19

 

 

Two UNIL-CHUV projects win InnoTREK/FIT innovation grant

July 6, 2020

Laurent Vinet and Lars Backhaus

PACTT is happy to announce that in response to the 2020 spring call InnoTREK/FIT, two projects from UNIL-CHUV were awarded an innovation grant.
These grants provide CHF 100’000.- financial support for the further development of an innovative project with a promising business potential in view of the creation of a start-up.

The project Artemis is developing an innovative, patented medical tool to meet a medical need in open surgical revascularization and vascular access. The biological mechanism leading to partial or total occlusion of blood vessels after surgical trauma is related to the development of intimal hyperplasia. Dr Laurent Vinet’s project aims to prevent restenosis of the vessels by releasing locally in a sustained manner drugs effective in the early and later phases of restenosis development, allowing a synergistic effect.
Dr Laurent Vinet will be hosted in Prof. Corpataux’s laboratory in the Cardiovascular Department at CHUV.

The project of Lars Backhaus named Intermedici is taking a completely new approach in digital medication. Intermedici’s products are based on the idea of MAGNA, a one-stop shop, AI-assisted online self-management database for different chronic diseases, in first line gout, rheumatoid arthritis and fibromyalgia. MAGNA will host disease specific data (clinical, patient reported, laboratory values, and wearables-derived) to document, analyze and improve patient care. The aim is to create clinically tested “digital drugs” for future prescriptions by doctors.

Mr Lars Backhaus will be hosted in Prof. Hugle’s laboratory in the Rheumatology Service at CHUV.

Nouvelle perspective de traitement pour le cancer non-musculo invasif de la vessie

June 15, 2020

 

La signature d’un contrat d’option exclusive entre le CHUV et Prokarium, négocié par le PACTT (Office de transfert de technologies UNIL-CHUV), permettra le développement en partenariat d’un nouveau traitement découvert au Service d’urologie.

L’Unité de recherche du Service d’Urologie du CHUV, dirigée par le Dr Denise Nardelli-Haefliger, a développé un nouveau traitement du cancer de la vessie non-musculo invasif (NMIBC en anglais) basé sur l’immunothérapie. Cette thérapie consiste en l’utilisation d’un vaccin Salmonella administré par voie topique dans le but de stimuler la réponse immunitaire contre la tumeur. (Pour plus de détails, voir les publications annexées). Un essai clinique de phase I avec le vaccin Ty21a est actuellement en cours au CHUV, sous la responsabilité du Prof. Patrice Jichlinski et du Dr. Ilaria Lucca. (Consulter le portail de l’Office fédéral de la santé publique (OFSP) consacré à la recherche sur l’être humain en Suisse)

La valorisation de cette recherche pour le bénéfice des patients, a débuté par le dépôt d’un brevet par le PACTT qui a accompagné les inventeurs (Dr D. Nardelli-Haefliger, Prof P. Jichlinski and Dr. S. Domingos Pereira) tout au long du processus vers la commercialisation.

La signature d’un accord d’option exclusif entre le CHUV et la compagnie de biotechnologie britannique Prokarium constitue une étape clé vers le développement de ce traitement.
Lire le communiqué de press de Prokarium.

Le cancer non-musculo invasif de la vessie touche chaque année 400’000 nouveaux patients dans le monde. Au vu des nombreuses ruptures de stock le traitement de référence, le vaccin Bacillus Calmette-Guérin (BCG), n’est pas disponible pour tous les patients et une autorisation temporaire de Swissmedic permet au Service d’urologie d’offrir un traitement avec Ty21a, le cas échéant.
Le Prof Beat Roth, nouveau Chef du service d’Urologie, se réjouit de poursuivre et développer la recherche et les études de ce nouveau traitement du cancer de la vessie.

 

Switzerland Innovation Tech4Impact Initiative 1st Call for Proposals

May 19, 2020

The objective of the “Switzerland Innovation Tech4Impact Initiative” is to facilitate and promote the development of ground-breaking innovation projects that focus on real market applications in collaboration with Swiss universities as well as entrepreneurs and SMEs collaborating with research/academic partners.

The first SI Tech4Impact Call for Proposals opens from 18 May until 31 July 2020. The grants (total of max. CHF 530’000 for the first round 2020) are financed by the innovation partners. The SI Tech4Impact initiative will award 5 to 7 selected projects with a one-year project grant ranging from CHF 70’000 – CHF 100’000 each.

More information is available at: https://sitech4impact.ch/

SI_Tech4Impact_Media_release_DE_FR_EN

 

Three InnoTREK grants awarded in 2019

February 10, 2020

In response to the 2019 autumn call InnoTREK, Mrs. Birge Ozel Duygan, Mrs. Loulia Kasem and Mr. Sylvain Perriot submitted three innovative projects. They were all three chosen to benefit individually from the InnoTREK grant of CHF 100’000.-. These funds will be a great help to continue developing their project and subsequently create their own start-up.

The project of Birge Ozel Duygan, named “CellCognize”, concerns incorporation of machine learned classified flow cytometry microbiota data in community diversity assessment.
Mrs Oezel Duygan will be hosted in Prof. Greub’s laboratory at the Microbiology Institute of the CHUV.

The project of Mrs. Loulia Kasem named “Rea” is issue from a work collaboration between the Centre Hospitalier Universitaire Vaudois (CHUV) and the Ecole Polytechnique Fédérale de Lausanne (EPFL). This project concerns a Smart Pad, which resolves a global medical need: inefficient diagnostics of preterm birth.
Rea’s technology is technically and clinically well-balanced and the two cofounders, Loulia Kassem and Erick Garcia Cordero, got simultaneously two grants of the Canton of Vaud : Innogrant of EPFL and InnoTREK of CHUV. Mrs. Kasem will be hosted in Prof. Baud’s laboratory at the Maternity of the CHUV.

The Project of Mr. Sylvain Perriot named “Glial therapeutics” consists of an in vitro model of human brain using stem cells derived from patients, which will be used to screen for drugs against multiple sclerosis. Mr. Perriot will be hosted in Prof. Du Pasquier’s laboratory in the department of clinical neurosciences at the CHUV.

The InnoTREK grant, managed by PACTT with the financial support of FIT (Fondation pour l’Innovation Technologique) as part of the InnoPACTT fund, supports selected researchers of UNIL and CHUV who have the ambition to venture into the business world with their innovative projects. These successful projects are chosen in a competitive process from applications received during the two calls per year. Since the launch in 2013, 19 laureates of UNIL and CHUV have benefited from the InnoTREK grant.